Concerning the PCa therapeutic treatments, authors found that IL-23+ cells can predict poor clinical outcomes in patients receiving the abiraterone treatment, while no similar effect was observed in patients undergoing docetaxel treatment [90]. This evidence concerns the gene IL23A and posterior cortical atrophy.